Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation

Journal of Molecular and Cellular Cardiology

Volumn 41, Issue 2, 2006, Pages 285-295

  Bousette, Nicolas ^a   Hu, Fu ^a   Ohlstein, Eliot H ^b   Dhanak, Dashyant ^b   Douglas, Stephen A ^b   Giaid, Adel ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Hemodynamics; Myocardial infarction; Receptors; SB 611812

Indexed keywords

2,6 DICHLORO N [4 CHLORO 3 [[2 (DIMETHYLAMINO)ETHYL]OXY]PHENYL] 4 (TRIFLUOROMETHYL)BENZENESULFONAMIDE; G PROTEIN COUPLED RECEPTOR; MESSENGER RNA; PLACEBO; SB 611812; UNCLASSIFIED DRUG; UROTENSIN II;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; CENTRAL VENOUS PRESSURE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; EMBRYO; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE CELL; HEART RIGHT VENTRICLE PRESSURE; HUMAN; HUMAN CELL; HYPERTROPHY; HYPOTHESIS; IMMUNOHISTOCHEMISTRY; LUNG EDEMA; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZATION; RAT; RNA ANALYSIS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; WESTERN BLOTTING;

ANIMALS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CELL SIZE; CORONARY VESSELS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HEART FAILURE, CONGESTIVE; HUMANS; LIGATION; MALE; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; RATS; RATS, INBRED LEW; SULFONAMIDES; UROTENSINS; VENTRICULAR FUNCTION, LEFT;

ANIMALIA;

EID: 33746062839     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2006.05.008     Document Type: Article

References (25)

1. Ames R.S., Sarau H.M., Chambers J.K., Willette R.N., Aiyar N.V., Romanic A.M., et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401 (1999) 282-286
2. Camarda V., Rizzi A., Calo G., Gendron G., Perron S.I., Kostenis E., et al. Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents. Naunyn Schmiedeberg's Arch Pharmacol 365 (2002) 141-149
3. Bohm F., and Pernow J. Urotensin II evokes potent vasoconstriction in humans in vivo. Br J Pharmacol 135 (2002) 25-27
4. Douglas S.A., Sulpizio A.C., Piercy V., Sarau H.M., Ames R.S., Aiyar N.V., et al. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 131 (2000) 1262-1274
5. Russell F.D., Molenaar P., and O'Brien D.M. Cardiostimulant effects of urotensin-II in human heart in vitro. Br J Pharmacol 132 (2001) 5-9
6. Sauzeau V., Le Mellionnec E., Bertoglio J., Scalbert E., Pacaud P., and Loirand G. Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ Res 88 (2001) 1102-1104
7. Watanabe T., Pakala R., Katagiri T., and Benedict C.R. Synergistic effect of urotensin II with serotonin on vascular smooth muscle cell proliferation. J Hypertens 9 (2001) 2191-2196
8. Tzanidis A., Hannan R.D., Thomas W.G., Onan D., Autelitano D.J., See F., et al. Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res 93 (2003) 246-253
9. Douglas S.A., Tayara L., Ohlstein E.H., Halawa N., and Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet 359 (2002) 1990-1997
10. Richards A.M., Nicholls M.G., Lainchbury J.G., Fisher S., and Yandle T.G. Plasma urotensin II in heart failure. Lancet 360 (2002) 545-546
11. Lapp H., Boerrigter G., Costello-Boerrigter L.C., Jaekel K., Scheffold T., Krakau I., et al. Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy. Int J Cardiol 94 (2004) 93-97
12. Johns D.G., Ao Z., Naselsky D., Herold C.L., Maniscalco K., Sarov-Blat L., et al. Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. Naunyn Schmiedeberg's Arch Pharmacol 370 (2004) 238-250
13. Rakowski E., Hassan G.S., Dhanak D., Ohlstein E.H., Douglas S.A., and Giaid A. A role for urotensin II in restenosis following balloon angioplasty: use of a selective UT receptor blocker. J Mol Cell Cardiol 9 (2005) 785-791
14. Dhanak D, Knight SD. Sulfonamide derivative urotensin-II receptor antagonists, preparation, pharmaceutical compositions, and therapeutic use. PCT Int. Appl. WO 2001045694; 2001.
15. Giaid A., Yanagisawa M., Langleben D., Michel R.P., Levy R., Shennib H., et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328 (1993) 1732-1739
16. Saito T., Hu F., Tayara L., Fahas L., Shennib H., and Giaid A. Inhibition of NOS II prevents cardiac dysfunction in myocardial infarction and congestive heart failure. Am J Physiol, Heart Circ Physiol 283 (2002) H339-H345
17. Behm D.J., Herold C.L., Camarda V., Aiyar N.V., and Douglas S.A. Differential agonistic and antagonistic effects of the urotensin-II ligand SB-710411 at rodent and primate UT receptors. Eur J Pharmacol 492 (2004) 113-116
18. Nguyen Q.T., Cernacek P., Calderoni A., Stewart D.J., Picard P., Sirois P., et al. Endothelin A receptor blockade causes adverse left ventricular remodeling but improves pulmonary artery pressure after infarction in the rat. Circulation 98 (1998) 2323-2330
19. Mulder P., Richard V., Derumeaux G., Hogie M., Henry J.P., Lallemand F., et al. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation 96 (1997) 1976-1982
20. Pfeffer J.M. Progressive ventricular dilation in experimental myocardial infarction and its attenuation by angiotensin-converting enzyme inhibition. Am J Cardiol 68 (1991) 17D-25D
21. Jain P., Korlipara G., Mallavarapu C., Sikand V., Lillis O., and Cohn P.F. Effects of captopril therapy after late reperfusion on left ventricular remodeling after experimental myocardial infarction. Am Heart J 4 Pt 1 (1994) 756-763
22. Lapointe N., Blais Jr. C., Adam A., Parker T., Sirois M.G., Gosselin H., et al. Comparison of the effects of an angiotensin-converting enzyme inhibitor and a vasopeptidase inhibitor after myocardial infarction in the rat. J Am Coll Cardiol 39 (2002) 1692-1698
23. Douglas S.A., Dhanak D., and Johns D.G. From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function. Trends Pharmacol Sci 25 (2004) 76-85
24. Boucard A.A., Sauve S.S., Guillemette G., Escher E., and Leduc R. Photolabelling the rat urotensin II/GPR14 receptor identifies a ligand-binding site in the fourth transmembrane domain. Biochem J 370 (2003) 829-838
25. Prinster S.C., Hague C., and Hall R.A. Heterodimerization of g protein-coupled receptors: specificity and functional significance. Pharmacol Rev 57 (2005) 289-298